 Aclaris Therapeutics Inc NASDAQ: ACRS has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis AD. The primary efficacy endpoint of this trial was the percent change from baseline in the modified Eczema Area and Severity Index mEASI score at week four. 